CGRP FORECAST: Early Success for Amgen?s Aimovig, But Intense Formulary Access Competition Between Similar Products Will Level the Playing Field

Text Registration

CGRP FORECAST: Early Success for Amgen?s Aimovig, But Intense Formulary Access Competition Between Similar Products Will Level the Playing Field

Status

Published

on 11 Sept 2019

Year of Creation

2018

IPD Analytics LLC

Registration Number

TX0008812814

on 11 Sept 2019

The U.S. Copyright record (Registration Number: TX0008812814) dated 11 Sept 2019, pertains to an electronic file (eService) titled "CGRP FORECAST: Early Success for Amgen?s Aimovig, But Intense Formulary Access Competition Between Similar Products Will Level the Playing Field" created in 2018. The copyright holder is IPD Analytics LLC, known for their creative contributions in text registration. For any inquiries concerning this copyrighted material, kindly reach out to IPD Analytics LLC.

IPD Analytics LLC

Application Details

Registration Number

TX0008812814

Registration Date

9/11/2019

Year of Creation

2018

Agency Marc Code

DLC-CO

Record Status

New

Corporate Author

IPD Analytics LLC

Physical Description

Electronic file (eService)

First Publication Nation

United States

Corporate Authors

IPD Analytics LLC

Statements

Application Title Statement: CGRP FORECAST: Early Success for Amgen?s Aimovig, But Intense Formulary Access Competition Between Similar Products Will Level the Playing Field

Author Statement: IPD Analytics LLC employer for hire Domicile: United States Citizenship: United States Authorship: text

Statements

Application Title Statement: CGRP FORECAST: Early Success for Amgen?s Aimovig, But Intense Formulary Access Competition Between Similar Products Will Level the Playing Field

Author Statement: IPD Analytics LLC employer for hire Domicile: United States Citizenship: United States Authorship: text

Get your copyright registered todayThousands have copyrighted their assets.
What are you waiting for?

Show terms & conditions

Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal advice. Although LegalForce RAPC Worldwide P.C., dba Trademarkia P.C., is a law firm (the “Firm”), your use of this website does not establish an attorney-client relationship with the Firm. Such a relationship can only be established after the Firm decides that it is willing and able to accept the engagement after a conflict check and after a written retainer agreement is agreed upon between you and the Firm. Your use of this website is also subject to our Terms of Use and Privacy Policy. ** The entry level subscription is a bundled price which requires a minimum of two billing cycles, or 6 months.